Background: There is a plethora of real-world data on the safety and effectiveness of direct-
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …

Background Recent reports suggest an important contribution from frequent off-label use of
apixaban 2.5 mg twice daily to the higher rates of thromboembolic events observed in …

In the present study, we aimed to provide evidence from high-quality real world studies for a
comprehensive and rigorous analysis on the gastrointestinal bleeding (GIB) risk for non …

Objetivos El objetivo consistía en evaluar un programa de gestión de anticoagulantes orales
directos (ACOD) en pacientes con fibrilación auricular no valvular (FANV) según sus …

Introduction Oral anticoagulation (OAC) is key in atrial fibrillation (AF) thromboprophylaxis,
but Spain lacks substantial real-world evidence. We aimed to analyze the prevalence …

Background Frequent monitoring of patients declined during the COVID-19 pandemic,
harming patients with chronic diseases who critically needed correct monitoring. We …

Aim: Healthcare resources usage and costs associated to nonvalvular atrial fibrillation
(NVAF) were analyzed in Spain. Methods: This is an observational and retrospective study …

Aims The aim is to evaluate a management program for direct oral anticoagulants (DOACs)
in non-valvular atrial fibrillation (NVAF) patients according to their profiles, appropriateness …

Abstract Introduction and objective In Spain, vitamin K antagonists (VKA) remain the
standard treatment for the prevention of thromboembolic and hemorrhagic complications in …

Background: Frequent monitoring of patients declined during the COVID-19 pandemic,
harming patients with chronic diseases who critically needed correct monitoring. We …